Category Archives: Genetics

Targeting the BFPs of the CNS, Biogen licenses map of genetic neighborhoods in the brain – Endpoints News

Searching for new methods of attacking serious central nervous system diseases, Biogen has signed a deal that could be run into the hundreds of millions of dollars to essentially license a transcriptional map of the brain and scan it for new drug targets.

The partnership, worth $15 million upfront and far more in milestones, is with a new bioinformatics startup called CAMP4 Therapeutics. Founded in 2018 year by the Whitehead Institutes Richard Young and Harvard Medical Schools Leonard Zon, CAMP4 takes genes considered affiliated with a disease and maps out the various ways cells express those genes and turn them on or off. They then take that map and in the biological equivalent of stretching a war map across a table in a bunker mark up all the different methods of attack.

The more we know about a gene, it doesnt mean we can drug that gene, CEO Josh Mandel-Brehm, who worked at Biogen before joining CAMP4, told Endpoints News. Many genes are not quote-un-quote druggable, so then we have an interesting problem: I think I understand the genetics of the disease, but how do I drug it? And thats where our map solves for this problem.

Alongside the $15 million upfront payment, CAMP4 will be eligible for up to $96 million in milestones for each of the initial targets it supplies, and up to $173 million for each subsequent one.

Biogen is not disclosing what genes or diseases they will target, but the collaboration will focus on microglial cells. These macrophages are found in the central nervous system and have long been considered a key factor in neurodegenerative diseases such as Alzheimers and Parkinsons.

Biogen will bring CAMP4 the genes it believes are central to diseases in the central nervous system, and CAMP4 will inform them all the ways the gene is being expressed and where Biogen might go about turning up or down the expression.

So you say hey I want to move this particular gene for this disease, how should I do that? I want to change the expression of it,' Mandel-Brehm said, describing how they work with partners. Well show you the different nodes, if you will: hey you can drug this, you can drug this, you can drug this. Its modality agnostic.

CAMP4, founded out of Polaris Partners, is one of a couple of new biotechs that build on a discovery Young had back in 2015. The longtime transcriptional biologist published work showing that cells modify gene expression using a series of insulated neighborhoods, 3-D loops of DNA that control gene expression within them. CAMP4 maps those (along with other aspects of the transcriptome). Flagship Pioneerings new Omega Therapeuticsalso tries to drug them.

Since launching in 2018, CAMP4 has done extensive work on mapping genes for liver diseases, including NASH, as part of an in-house development program. Theyve also partnered with synthetic RNAi company Alnylam and are working to expand their maps of cells in the brain, heart, muscles, immune system, blood and kidneys, which they could then license out or use to develop drugs in-house.

The way I think about the diseases were going after is BFP: Big Fucking Problems,Mandel-Brehm said, citing NASH and other diseases that lack effective treatments. And Its well-validated and understood: If youre drugging something thats tied to the gene, youre much more likely to be successful.

Read more here:
Targeting the BFPs of the CNS, Biogen licenses map of genetic neighborhoods in the brain - Endpoints News

Genetics | Science | The Guardian

Requiring minimal amounts of sleep is sometimes seen as a badge of honour. But for many of us, being able to actually function is a different matter altogether. So why is it that some people seem to need more or less sleep? And what are some of the ramifications if we dont get enough? Hannah Devlin speaks to two experts whose work is bringing new understanding to our sleeping behaviours

Read the original:
Genetics | Science | The Guardian

Empirico Announces Strategic Collaboration to Harness Human Genetics for the Discovery and Development of Novel Antisense Oligonucleotide Therapeutics…

Empirico Inc. announced today that it has entered into a strategic collaboration with Ionis Pharmaceuticals. During the three-year collaboration, Empirico will utilize its Precision Insights Platform, which incorporates huge biological data sets, human genetics and advanced algorithmic approaches, to identify therapeutic targets for indications and tissues that are amenable to Ionis industry-leading antisense technology. Under the terms of the agreement, Ionis can advance up to ten targets identified by Empirico and assume responsibility for all preclinical and clinical development activities. Empirico and Ionis will also work together to incorporate human genetics evidence into ongoing efforts with existing Ionis programs, including work on target validation, indication and biomarker selection, and patient stratification.

Empiricos Precision Insights Platform was purpose-built for therapeutic target discovery and incorporates one of the largest datasets of its kind in the world to interrogate the role of genes and proteins in health and disease and find opportunities for novel therapeutic interventions. By combining expert data curation, customized data models, and statistical and machine learning algorithms, the platform enables Empiricos scientists to systematically generate, interrogate, and prioritize high-confidence therapeutic hypotheses that are then validated experimentally.

"Empiricos approach to human genetics provides a much-needed opportunity to improve the success rate of drug discovery and development by leveraging experiments of nature," said Omri Gottesman, M.D., CEO of Empirico. "Antisense oligonucleotides are an ideal translational partner for human genetics-focused target discovery, allowing us to precisely mimic or interfere with the mechanisms by which functional genetic variants influence health and disease. We are excited to work with Ionis, the leader in RNA-targeted drug discovery and development, in discovering new medicines for patients in need."

As part of this new collaboration, Ionis has made a $10 million equity investment in Empirico, with additional near-term commitments of up to $30 million based on operational and preclinical milestones. Empirico will be eligible to receive in excess of $620 million for the achievement of clinical development, regulatory and commercial milestones, and royalties on net sales. Empirico also has the option to license, develop, and commercialize an Ionis development candidate directed toward a collaboration target for which Ionis will receive milestone payments and royalties on net sales.

In connection with this new collaboration, Empirico also announced today the closing of its $17 million Series A-2 financing, led by Ionis and with participation by DCVC Bio and Neotribe Ventures. This was a follow-on round to Empiricos $12.5 million Series A financing, co-led by DCVC Bio and Neotribe Ventures and completed In November 2018.

About Empirico

Empirico is a next-generation therapeutics company founded on utilizing human genetics, data science and programmable biology to power novel target discovery and development. Empiricos Precision Insights Platform, a proprietary human genetics-focused discovery platform, leverages a world-leading dataset and advanced algorithmic approaches to identify and prioritize therapeutic targets with a higher probability of translational success. All potential therapeutic targets are subjected to rigorous experimental validation to elucidate the mechanism by which genetic variation impacts disease risk and provide insights about which therapeutic modality could be programmed to mimic or interfere with that mechanism. Empirico has active preclinical development programs across several immune, dermatological, cardiometabolic, and ophthalmic indications based on targets identified with the Precision Insights Platform. Empirico is headquartered in San Diego, Calif. with laboratories in Madison, Wis. To learn more about Empirico, visit http://www.empiricotx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005091/en/

Contacts

Media Contact: Jessica Yingling Ph.D.Little Dog Communications Inc. jessica@litldog.com +1-858-344-8091

Read more:
Empirico Announces Strategic Collaboration to Harness Human Genetics for the Discovery and Development of Novel Antisense Oligonucleotide Therapeutics...

Genosity, Columbia University Partner to Study Genetics of Rare Heart Condition – GenomeWeb

NEW YORK Genosity said on Tuesday that it has partnered with Columbia University to investigate the genetic underpinnings of wild-type cardiac amyloidosis, a rare condition characterized by the accumulation of abnormal proteins in the heart.

Although there is a heritable form of cardiac amyloidosis called transthyretin-related (TTR) amyloidosis that is caused by mutations in the gene that encodes the protein transthyretin, some individuals develop the disease without such mutations.

Originally posted here:
Genosity, Columbia University Partner to Study Genetics of Rare Heart Condition - GenomeWeb

Autism heritability: It probably does not mean what you think it means – Spectrum

Brian Lee

Associate professor, Drexel University

The question of autisms heritability is compelling for researchers and laypeople alike, but many people in both groups misunderstand its definition.

Heritability is defined as the proportion of variation in a condition that is attributable to variation in genetics. Heritability estimates can influence how much time and money researchers like me think should be allocated to studying genetic factors versus environmental ones. For families with a history of autism, heritability estimates get right to the heart of the nature-versus-nurture debate, by offering clues about which factors led to an individuals diagnosis.

These numbers have substantial implications; they probably should not. Autism arises from a complex interplay of genetic and environmental factors, and most heritability studies oversimplify these relationships.

Several studies on autism heritability published in the past few years have drawn considerable attention. Those published from 2011 to 2014 estimated heritability to be in the 35 to 50 percent range, but studies published since 2017 have put the number at 64 to 85 percent.

What do these estimates actually mean?

Heritability is often misinterpreted as the proportion of a condition that is caused by genes. However, that interpretation is not quite correct. Or rather, so many asterisks must be attached in order for it to be correct, that it could not be, by any stretch of the imagination, considered to be correct.

Heritability estimates may tell us to what extent a persons genetics predispose them to a condition. But they tell us nothing about how different environments cause those genetics to play out.

First, let me explain why most estimates of heritability are incorrect. Studies that estimate autisms heritability use a statistical model to try to attribute the condition to either genetics or environment. Mounting evidence suggests this model is too simplistic to explain how autism arises.

The model generally looks something like this: Observed characteristics, or phenotype (P) = genotype (G) + environment (E). The G and E components can each be broken down further to get at specific types of genetic or environmental contributions, but the core point of the model is to separate G and E.

A statistical model is merely a caricature of the real world, though; the extent to which it is useful depends on how well the model reflects reality. The P = G + E model assumes that genetic and environmental influences are independent of each other and that genes do not interact with the environment or with other genes to influence phenotype.

We know in fact that networks of genes interact to influence a persons odds of having autism and that genetic factors raise the odds of having autism caused by environmental exposures such as infection, air pollution or nutrition.

In short, if reality is more complex than the model, that model may produce inaccurate heritability estimates. There are many more technical reasons why published heritability estimates are likely to be inaccurate1.

There is also a much simpler reason why heritability estimates should not be taken at face value: High heritability does not equal genetic causation, and it does not exclude the possibility of environmental influence.

Here are two thought experiments that demonstrate why.

Borrowing an example from the great evolutionary biologist Richard Lewontin, imagine planting a set of identical seeds in a uniform environment that ensures all the seeds receive equal amounts of light and nutrients. Any variation in the heights of the plants that grow from those seeds is solely attributable to genetic variation among the plants. The heritability in this scenario is 100 percent.

Now imagine taking another set of the same seeds and planting them in uniformly suboptimal growing conditions, with limited light and nutrients. The plants growth would be stunted, and again the heritability would be 100 percent.

The point is: Even where heritability is estimated to be 100 percent, the environment can influence phenotype. Of course, this is not limited to plants. For example, the heritability of human height is estimated to be approximately 80 percent, but height is still strongly regulated by a persons nutritional environment.

Next, consider this example from David S. Moore and David Shenk2. Imagine a bucket of water into which person A pours 40 liters of water and person B pours 60 liters of water. Clearly, 40 percent of the water is attributable to person A, 60 percent to person B. Now imagine the same bucket, but this time person A turns on the faucet and person B holds the hose. How much of the water in the bucket is due to person A and how much is due to person B?

In short, when causes interact to create an outcome, it becomes nonsensical to try to apportion credit (or blame) to one cause independent of the other.

The bucket example is not just a thought experiment; it represents conditions that have both genetic and environmental components.

Consider the condition phenylketonuria, which occurs in people who have genetic variants that affect how their bodies metabolize the amino acid phenylalanine. The condition does not occur in the absence of the genetic variants, but it also does not occur if phenylalanine is removed from the diet. So how much of it can be attributed to genes versus the environment?

The consequences of miscasting heritability as the contribution of genetics to any given individuals diagnosis are potentially dire. As well as misinforming the public, it could throw funding for research on the etiology of autism entirely into genetic research rather than into how genes and environment interact.

This should cause genetic and environmental researchers alike great concern.

The search for rare genetic variants that may cause autism has yielded many important findings, but the search for common variants, whose influence combines to raise autisms odds, has been less fruitful. There are likely to be many of these variants, each exerting only weak effects, which makes them undetectable except in massive study samples. It is also highly likely that many common variants do not exert an effect unless they are present along with another genetic or environmental factor.

Animal models that explore genetic factors in the absence of relevant environmental interactions could be doomed never to recapitulate those genetic factors effects in people.

In short, many heritability estimates of autism in the literature are likely to be inaccurate and, more importantly, prone to misinterpretation. Rather than asking: Are genes or the environment responsible for autism? we should be asking: How are genes and the environment responsible for autism?

Brian Lee is associate professor of epidemiology and biostatistics at Drexel University in Philadelphia, Pennsylvania.

See the rest here:
Autism heritability: It probably does not mean what you think it means - Spectrum

Second Annual Medical Genetics Awareness Week Will Be Celebrated March 17-21, 2020 – P&T Community

BETHESDA, Md., Jan. 7, 2020 /PRNewswire/ --The second annual Medical Genetics Awareness Week will be celebrated March 17-21, 2020. Through Medical Genetics Awareness Week, the American College of Medical Genetics and Genomics (ACMG) aims to promote awareness of the importance of medical genetics professionals, including medical geneticists, laboratory geneticists, genetic counselors, nurses and physician assistants, on the healthcare team. The theme of Medical Genetics Awareness Week is "Celebrating the Contributions of the Entire Medical Genetics Team to Patient Care."

New for 2020 are dedicated medical genetics awareness web pages available at http://www.acmg.net/medicalgeneticsawareness. These pages offer a wide range of resources including tips on how to become an ambassador for medical genetics in your workplace and community; a resource tool kit with suggestions for medical genetics-related activities and tools for use on social media; and information on careers in medical genetics.

Medical Genetics Awareness Week is celebrated to recognize the invaluable contributions that medical genetics healthcare professionals make in the diagnosis, management and prevention of genetic diseases, and the difference these professionals make in the lives of patients and families. Medical Genetics Awareness Week is also intended to educate other healthcare professionals, students and trainees on who medical geneticists are, how they are trained and what they do in the clinic and laboratory.

"As medical genetics and genomics finds a home in healthcare systems across the country, remember the valuable role that the medical and laboratory geneticist plays in delivering high quality high value care," said Anthony R. Gregg, MD, MBA, FACOG, FACMG. "Some in our community have more than 10 years of laboratory and/or clinical training after college. Our disciplines attract the "best in class." As we speak with and care for our patients, we are reminded that it is a privilege to be a part of the medical genetics teama team that includes care providers across the clinical spectrum."

Events related to Medical Genetics Awareness Week will be held during the ACMG Annual Clinical Genetics Meeting in San Antonio, Texas (www.acmgmeeting.net) March 17-21, 2020. The ACMG Annual Meeting is the largest conference specifically for clinical geneticists in the United States. Those interested in collaborating with ACMG to celebrate Medical Genetics Awareness Week, holding their own event or becoming an "ambassador" for medical genetics are invited to email rsantos@acmg.net for more information.

"As a practicing clinical geneticist I have been working with individuals dealing with a genetic issue in their family for over three decades," said Maximilian Muenke, MD, FACMG, ACMG'schief executive officer. "It has been a privilege to meet and accompany families over the years and learn from their challenges and how many of them grow in the process. Even though the overall numbers of healthcare professionals in medical genetics have grown, the demand for genetics services has grown even faster. Based on the preliminary data analysis of the NCC Medical Genetics Workforce Survey, a study initiated by the American College of Medical Genetics and Genomics, wait times to make an appointment with a medical geneticist are too long in many parts of the US. It is my hope that the Medical Genetics Awareness Week will increase knowledge of our profession in the general population and compassion for those affected by genetic conditions."

In 2019, the first ever Medical Genetics Awareness Week brought together people from across the globe to raise awareness of the important work of medical geneticists. The success of the 2020 celebration will once again rest on the participation of people everywhere. ACMG invites you to help 2020's celebration set new records for engagement by visiting the new Medical Genetics Awareness Week web pages and using the resources and tools we offer to support your celebrations. Be sure to tag @TheACMG on social media and include the following hashtags in your social media posts related to Medical Genetics Awareness Week:

#MedicalGeneticsAwareness#IamaMedicalGeneticist#FutureGeneticsProfessional#IamaLabGeneticist#IamaGeneticCounselor#IamaNurseinGenetics#IamaGeneticsPA

About the American College of Medical Genetics and Genomics (ACMG) and ACMG Foundation

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical society dedicated to improving health through the clinical practice of medical genetics and genomics and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,300 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Kathy Moran, MBAkmoran@acmg.net

View original content to download multimedia:http://www.prnewswire.com/news-releases/second-annual-medical-genetics-awareness-week-will-be-celebrated-march-17-21-2020-300981277.html

SOURCE American College of Medical Genetics and Genomics

Continued here:
Second Annual Medical Genetics Awareness Week Will Be Celebrated March 17-21, 2020 - P&T Community

Is ‘No Kill’ Changing the Genetics of Pit Bulls? – City Watch

But a newphenomenon is also developing as a common occurrence -- multiple Pit Bulls attacking as a pack.

Colleen Lynn, founder ofDogsBite.org,which tracks and investigates fatal dog maulings, reports that,of all fatalities,65% involved two or more dogs, a reversal from early CDC (Centers for Disease Control) study years when 70% of fatalities involved a single dog.

Could the number of dogs involved in attacks listed below signal that these expanding policies -- which allow unlimited adoption, ownership, or keeping of Pit Bulls per household be influencing and changing the genetics of Pit Bulls -- and not in a good way?

The following is a single Pit Bull attack that occurred recently.I am providing it to show what was required to stop this dog in an enclosed location with animal-handling experts present.Imagine the terror and damage if there had been more Pit Bulls involved:

Attacking Pit Bull Shot in Animal Shelter to Save Life of Supervisor

Here is a terrifying example of the relentless nature of a Pit Bull attack. It was recorded on the kennel video in the Oakland County animal shelter and reported this week by theDetroit Free Press. The severely injured supervisor was a 25-year veteran of animal care and control.

The four-year-old Pit Bull involved, Roscoe, and had been surrendered after he attacked an adult and two children in the family that had reportedly loved and raised him since a puppy.

"When three Oakland County dog shelter workers couldnt dislodge a ragingpit bull mauling the kennel supervisor, a policeofficer shot thedog in the head, saving the supervisor. . . Yet, the 80-pound dog after being shot at point-blank range, between the eyes, seemingly rose from the dead, the Oakland County spokesman said.

The officer returned to the hallway of the six kennels housing dangerous dogs and found that the pit bull had regained consciousness and "now posed a fresh threat."

The officer saw it was now a wounded animal and the possible threat played through his mind, so he immediately ended its suffering with a second shot that was fatal," the spokesperson said.

The report states that,even after the incident was conveyed to the family, the mother refused to give permission to euthanize the dog, blaming the serious attack on herself and her two children to the fact she had been "talking too loud."

Roscoe had also previously bitten a shelter worker who took him out for a walk.

RECENT ATTACKS BY MULTIPLE PIT BULLS

Three Pit Bulls Kill Womanin Houston, TX on December 21, 2019.DogsBite.orgreports one woman is dead and another severely injured after a vicious dog attack in north Houston, according to police. . .KTRK reports thatall three dogs are pit bulls.

Woman Attacked by 6 Pit Bulls While Walking Dog. . .

Apr 26, 2019 -Awomanis recovering after police say she wasattackedbysix pit bullswhile walking her daughter's dog Wednesday night in Taunton, Massachusetts.. . .The officer then witnessedsix pit bullsfollowing andattacking51-year-old Rochelle Silva.

4 Pit Bulls Attack Woman Walking Dog. . .

Jun 24, 2019 -Awomanwas recovering after she wasattackedbyfour pit bullswhile walking her roommate's dog in Calgary, Canada, on Friday night.

Woman critically injured in Maryland pit bull attack

Nov 14, 2019 -Awomanwas critically injured in anattackby twopit bulls. . .Helicopters were used to searchforthe dog. . .

5 Pit Bulls Attack Woman On Bike, 'Tore Her Apart', Husband. . .

Apr 2, 2019 -A Florida woman underwent surgery Monday after suffering serious injuries following anattackbyfive pit bullson March 28.

Five Pit Bulls Maul Philadelphia Toddler to Death

Aug 2, 2018 -A 2-year-old boy was mauled to death byfive pit bullsat his aunt's house in the Port Richmond area of Philadelphia, local police have said. Officers responding to the incident at around5:35 p.m. Wednesday fired at the dogs to stop theattack, killing one and injuring two others, reported WPVI.

For shocking and informative quick-stats and graphs, see:Deadly Dog Attacks.

Read also:CA Hits Record High in Fatal Dog Attacks in 2019 -- Are Animal ControlPolicies Protecting Us?

HISTORY:PIT BULLSUSED FOR FIGHTING - NOT NANNY DOGS

Human aggression by Pit Bulls was not acceptable in past generations, including by dog fighters.The early 1900's photos which are now purported to be "Nanny Dogs" were actually ads used to show that the breeding stock by a dog man was NOT human aggressive and would not attack a human at a dog fight/match -- it did not mean they were house pets.

Dog fighting was legal in the U.S. at that time and advertising Pits bred for that purpose was rampant. They were bred to attack another dog without provocation andkill quickly and efficiently. They werenotintended to be released into society.(Google 'Pit Bulls for Sale' ads in the early 1900's inDog Fanciermagazine.)

PIT BULLS THAT ATTACK HUMANS NOT KEPT BY DOG FIGHTERS

Following an ad for pups from the line of "Old Family Red Noses and "Red Devils" with photos of "Wilder Red Inferno" and "Mean Girl, " here areexcerptsfrom an op-ed that appears in theAmerican Pit Bull Terrier Gazette(FALL 1997).

SIMPLY RETROSPECT OR RESPECT?(by Charlie Stephens,President, Lone Star APBT Club.)

"LET'S LOOK AT THE 1920'S AND1930'S. Things were very different then.We went to church on Sunday with no thought of burglary or theft, and the dog we had didn't dare bite a human being.If a dog, any dog, was aggressive toward humans it was killed.No, not gassed or injected, it was shot! It was a simple time and that type of dog simply was not tolerated.And this was especially true for the American Pit Bull Terrier. Dogmen of the 1920's and '30's would not allow it!

Today, however, it is different.People are scared, real scared, and they believe they need protection.So, they go out and buy a dog.

(He mentions five incidents of APBT attacks.)

In closing, I make a plea to all dog owners of America. Please take responsibility for your dog. . . If you must own a dog that is human aggressive, then keep it away from humans.And, keep it away from windows too.

PIT BULLS/FIGHTING DOGS CHANGED BY ADAPTATION

AJanuary 18, 2019 article, "The so-called modern bloodlines,"byNeylor Zaurisio, discusses and documents his personal study ofhow, since the 1800's, modern living necessitated adaptations that changed the name of the breed and also affected its size.

"In the late 1800's,with the industrial revolution, thousands of families migrated from rural areas to large industrial centers in search of employment.

Some of these families had as a form of extra income and tradition sold and bet on fighting dogs, Pit Bull dogs. When they saw the opportunity of a better future in the big cities they started to move and took their dogs with them, changing drastically from a habitat where they developed completely, to small spaces in apartments and other cheap options where they were confined most of the time, [loss of] exercise and losing their habit, combined with the selection for smaller dogs, caused a visible reduction in muscular and bone structure.

PIT BULLS HAVE ALSO ADAPTED BY SELECTIVE BREEDING

Pit Bull genetics have been changed several times.In theUnited Kingdom, bull-and-terriers were used inblood sports, such as,bull baitingandbear baitinguntil this was officially eliminated in 1835 when Britain introducedanimal welfare laws.

Sincedog fightingis cheap to organize and far easier to conceal from the law, blood-sport enthusiasts begin to develop dogs that could be pittedagainst each other.

DOG FIGHTERS OPPOSE BSL AND "MANDATORY SPAY/NEUTER"

Dog fighting was used as both a blood sport (usually involving gambling) and a way to continue to test the gameness and maintain fighting blood lines. Maintaining these bloodlines is the reason dog fighters do NOT want "Breed Specific Legislation" (BSL) nor mandatory spay/neuter laws.

If this centuries-old lineage is destroyed, it cannot be replicated.The characteristic of "gameness" means the animals will attack and kill without provocation--includingits own breed.It also means it will continue to fight until it is dead or physically incapable of movement.

PIT BULLS HISTORICALLY KEPT IN ISOLATION

Pit Bulls have traditionally been kept as the only dog in a household, chained or caged in isolation because of their propensity to attack/kill. (Dog fighters keep them caged or "tied out" on chains in their yards.A yard can be any size property, and many keep dozens of dogs -- each far enough from the others to be unable to engage physically. They did not indulge in "play groups."

MULTI-DOG HOUSEHOLDS, NO BSL AND NO PET LIMITS

The "No Kill" movement as prescribed by Best Friends Animal Society has imposed rigid rules for animal shelters and animal owners regardingeuthanizing a dangerous dog, and many veterinarians are afraid to take this risk because of the criticism that can be generated on the Internet.

Prior to this, rules and laws of animal ownership were created and enforced for public and animal health and safety, animals were limited to the number that did not create excessive noise and exhibit behavior issues that decreased or threatened the safety and quality of life of a community.

Best Friends policies links:

Save Them All - Best Friends Animal Society- Best Friends Animal Societyis leading the way.

Best Friends Position Statements on Issues -BestFriendsis opposed tomandatory spayandneuterlaws.

Dog Breed Labels | Best Friends Animal Society-Apr 6, 2018-Labelingshelterdogs as a particularbreedis problematic.Shelterstaff are wrong a majority of the time when identifying a dogs prominent breed. . .

Pet Limit Laws in Los Angeles | The Best Friends Blog

Dec 14, 2010 -Los Angeles is looking to raise itsanimal limit laws. Five reasons whypet limitsare a bad idea in the first place.

Pit Bulls, Dog Breed Discrimination & BSL | Best Friends.

One ofBest Friends' primary goals is to end pit bull breed discrimination,breed-specific legislation(BSL) and the killing of pit bulls in shelters.

Read also:Best Friends Animal Society in Dog Fight over Shock Collars(Nov 25, 2019)

MULTIPLEPIT BULLSMAY BE THE NEXT GATHERING STORM

In 1990, Donald H. Clifford, DVM, and two other noted staff members at the medical College of Ohio, published THE PIT BULL DILEMMA - The Gathering Storm," annotating 1.000 abstracts from books, journals, magazines, newspapers and reports of dog fighting and Pit Bull Attacks.

This was a warning that a new threat was being unleashed on society.(CA enacted a No Breed Specific Legislation prohibition in 1989.)

After Pit Bulls began to be kept as pets, owners generally kept only one orperhaps with a dog of the opposite gender (but even this may not stop them from inevitably fighting or killing each other.)

However, the basic behavior seems to be changing--perhaps as an adaptation to multiple-Pit households--so that numerous Pit Bulls can live together without killing each other but attack as a pack.Is this an anomaly, or is there a change occurring in the genetic structure of the dogs?

IS THE MULTIPLE-PIT BULL ENVIRONMENT CHANGING THE GENETICS OF PIT BULLS?

In the study, "Both Environment and Genetic Makeup Influence Behavior," the following conclusion was reached:

How do genes and the environment come together to shape animal behavior? Both play important roles. Genes capture the evolutionary responses of prior populations to selection on behavior. Environmental flexibility gives animals the opportunity to adjust to changes during their own lifetime.

I am not a geneticist, but I think it is worth questioning whether creating a living environment for Pit Bulls as pets in large or unlimited numbers in the same household is also creating changes in genetics which allows them to act in unison during attacks, but not turn on each other?

And, if so, judging from the recent increase in multiple Pit Bulls attacking as a pack, what issues does this pose for the future of society and community safety?

(Phyllis M. Daugherty is a former City of Los Angeles employee and a contributor to CityWatch.) Edited for CityWatch by Linda Abrams.

See the article here:
Is 'No Kill' Changing the Genetics of Pit Bulls? - City Watch

Scientists Figured Out the Indian Cobra’s Genomeat Last – WIRED

In 1891, a French physician named Albert Calmette opened a research outpost in what was then Saigon (now Ho Chi Minh City, Vietnam) to develop new vaccines for rabies and smallpox. Then the Indian cobras showed up.

The invaders sank their fangs into several of Calmettes new neighbors, injecting molecules that rotted muscles, ruptured blood vessels, and paralyzed the nerves that told their hearts to beat and lungs to breathe. Their grisly deaths prompted him to drop infectious disease and focus on snake venom. When he returned to France, he injected Indian cobra venom into rabbits in small doses and discovered that the animals produced a serum with a protective effect: the first antivenom. Calmette began producing his anti-cobra cocktail of antibodies in donkeys and horses and in 1895, for the first time, successfully treated a human snakebite victim.

Calmettes method still dominates antivenom production todaya practically medieval process of snake milking and horse blood harvesting that is laborious, expensive, and error-prone. What scientists have needed in order to modernize this operation is the source code for a snakes noxious protein soup, the actual genes and nearby DNA that turn them on or off.

After two years of work, an international team of scientists has now published, in Nature Genetics, an atlas of all 38 of the Indian cobras chromosomes, the most complete snake genome ever assembled. It contains information no one has ever been able to piece together before: the genetic recipe for the snakes deadly venom cocktail. Theyre hoping it will serve as a roadmap to bring antivenom production into the 21st century.

It seems like something we should have figured out 20 years ago, but until now those areas of the snake genome have been total black boxes, says Todd Castoe, an evolutionary geneticist at the University of Texas at Arlington who was not involved in the work. Initially, scientists believe, the genes that generate venoms carried out totally different functions, usually some innocuous cellular housekeeping task. But along the way they duplicated, a common DNA-copying error. And then the extra copies acquired mutations. That happened over and over, and the proteins they produced became deadly in different ways. The result of all this evolution is that the stretches of DNA that code for venom toxins are full of repetitive sequences, making them exceedingly difficult to properly assemble. Imagine trying to solve a jigsaw puzzle where the same fluffy clouds are scattered six, eight, a dozen times in the same corner of the sky. How do you know which piece goes where?

To finally fit together these elusive sections of the genome, Somasekar Seshagiri, a geneticist and president of the SciGenom Research Foundation in Bangalore, and his collaborators used a combination of older sequencing methods with new ones that read out very long stretches of DNA. They also employed a technique that detects the 3D shape of DNA to further refine their guesses about how exactly to stitch together the structurally finicky venom regions. With the full genome in hand, the researchers then analyzed which sections of it are turned on in the venom gland but not in other tissues. That allowed them to identify the code that spells death or disablement for anyone who encounters the cobras bite.

Antivenoms will no longer just be like some magic potion we pull out of a horse.

Somasekar Seshagiri

Indian cobra venom isnt just one poison; it consists of more than a dozen toxins and other substances that together launch a coordinated attack on the snakes prey (or a hapless human victim). In the Nature Genetics paper, Seshagiris team identified 19 genes key to producing this lethal brew. For the first time, it establishes the links between a snakes toxins and the genes that encode them.

The achievement not only shows scientists how to use the same methods to sequence other venomous snake species, it also unlocks the door to modernizing antivenom production. The value of genomics is that it will allow us to produce medicines that are more concretely defined, says Seshagiri. Antivenoms will no longer just be like some magic potion we pull out of a horse.

See the article here:
Scientists Figured Out the Indian Cobra's Genomeat Last - WIRED

Nature Reviews Genetics Pseudogene Function Is Prematurely Dismissed – Discovery Institute

A new paper in Nature Reviews Genetics, Overcoming challenges and dogmas to understand the functions of pseudogenes, is simply incredible. It documents not only that pseudogenes have been found to have widespread function but also that under current dogma in biology, and given the technical limitations, we are failing to recognize their functions. As Seth W. Cheetham and his co-authors put it, biology suffers from demotivation into exploring pseudogene function by the a priori assumption that they are functionless where The dominant limitation in advancing the investigation of pseudogenes now lies in the trappings of the prevailing mindset that pseudogenic regions are intrinsically non-functional.

The abstract lays out exactly what they think:

Pseudogenes are defined as regions of the genome that contain defective copies of genes. They exist across almost all forms of life, and in mammalian genomes are annotated in similar numbers to recognized protein-coding genes. Although often presumed to lack function, growing numbers of pseudogenes are being found to play important biological roles. In consideration of their evolutionary origins and inherent limitations in genome annotation practices, we posit that pseudogenes have been classified on a scientifically unsubstantiated basis. We reflect that a broad misunderstanding of pseudogenes, perpetuated in part by the pejorative inference of the pseudogene label, has led to their frequent dismissal from functional assessment and exclusion from genomic analyses. With the advent of technologies that simplify the study of pseudogenes, we propose that an objective reassessment of these genomic elements will reveal valuable insights into genome function and evolution.

They immediately caution that there are many instances where DNA that was dismissed as pseudogene junk was later found to be functional: with a growing number of instances of pseudogene-annotated regions later found to exhibit biological function, there is an emerging risk that these regions of the genome are prematurely dismissed as pseudogenic and therefore regarded as void of function.

In 2003, Francisco Ayala and Evgeniy Balakirev wrote in Annual Review of Genetics that pseudogenes that have been suitably investigated often exhibit functional roles. This new Nature Reviews Genetics paper offers a very similar statement: Where pseudogenes have been studied directly they are often found to have quantifiable biological roles. Its a long narrative that recounts how many scientists mistakenly dismissed stretches of DNA as pseudogenes. They document dozens of instances where pseudogenes in humans and other organisms have been found to have function.

Some of these functions are protein-based, meaning the pseudogene actually generates a functional protein. But other functions can be RNA-based or DNA-based. For example, most evolutionists would presume that a pseudogene that does not produce a protein cant be functional. But the paper observes that pseudogenes that cannot be translated into a protein may still have a function through their RNA transcript:

Many pseudogenes contain a frequency of mutations that render them unlikely to be (or incapable of being) translated into proteins. However, such mutations do not necessarily preclude pseudogenes from performing a biological function.

The paper notes that even if the RNA transcript of a pseudogene cant be translated into protein, a myriad of RNA-based regulatory mechanisms have been described for pseudogenes, including processing into small interfering RNAs (siRNAs) that may regulate their parent genes, acting as a decoy for transcription factors and, most prominently, as molecular sponges for microRNAs.

Many evolutionists would forcefully assume that if a pseudogene cant even produce an RNA transcript then it cant be functional. But it turns out that pseudogenes that dont produce any RNA transcript (i.e., arent transcribed) can still have important functions:

Another mechanism through which pseudogenes can function is by influencing chromatin or genomic architecture. HBBP1, a pseudogene residing within the haemoglobin locus, enables the dynamic chromatin changes that regulate expression of fetal and adult globin genes during development. Notably, although inhibiting HBBP1 transcription has no effect, deletion of the genomic locus reactivates fetal globin expression. HBBP1 DNA contacts, but not transcription, are required for suppressing the expression of fetal globin genes in adult erythroid cells.

A variety of other non-transcriptional functions are documented in the paper, including stabilizing chromosomes, mediating transcript-splicing, and regulating recombination. Thus, in many cases copy numbers of pseudogenes seem to have functional importance, where deviations from the normal genetic state causes disease. They predict: It is expected that further links between human pseudogene polymorphisms and complex diseases will be identified in the coming years

The implication is that one reason we presume pseudogenes are functionless is because we havent been looking for their functions. And why didnt we look for their functions? Because we presumed they were functionless! So theres a circular aspect to the reasoning here. It has created the science-stopping junk-DNA paradigm, which has prevented us from understanding what pseudogenes really do.

The typical response from evolutionists would be that all of these examples of functional pseudogenes are just isolated rare cases, and that the bulk of pseudogenes are clearly junk. The authors of the paper who give no indication of sympathy for intelligent design, but definitely oppose dismissing pseudogenes as junk are aware of this objection. They say the following in direct rebuttal to it:

The examples of pseudogene function elaborated on here should not imply that pseudogene functionality is likely to be confined to isolated instances. At least 15% of pseudogenes are transcriptionally active across three phyla, many of which are proximal to conserved regulatory regions. It is estimated that at least 63 new human-specific protein-coding genes were formed by retrotransposition since the divergence from other primates. Numerous retrogenes continue to be recognized as functional protein-coding genes rather than pseudogenes across species. High-throughput mass spectrometry and ribosomal profiling approaches have identified hundreds of pseudogenes that are translated into peptides. Although the functions of these peptides remain to be experimentally determined, such examples illustrate the challenge in substantiating a genepseudogene dichotomy.

They continue: As the abundance of such [non-coding-DNA] acquired functions does not appear to be an especially rare or isolated phenomenon, it would seem remiss to take the default perspective that processed pseudogenes are functionless. Instead, it is probable that pseudogene-containing regions of the genome harbour important biological functions that are yet to be revealed.

They point out that current algorithmic and computational methods employed for differentiating pseudogenes and protein-coding genes may overestimate the proportion of the genome that is composed of pseudogenes. Why? Because the properties that are used to define many pseudogenes are also often found in normal protein-coding genes. For example:

Because of this, they argue that computational differentiation of pseudogenes from genes on a purely rule-based system is unlikely to be feasible as it will inherently conflict with many protein-coding genes. They therefore propose markedly softening claims that a stretch of DNA is a pseudogene: it may be useful to consider the annotation of pseudogenes in genomes as a prediction or a hypothesis rather than a classification.

As the authors show, the presumption that a pseudogene is functionless needs to be abandoned. But then, why are we still presuming they are functionless? There are three main reasons: (1) evolutionary thinking has presumed that pseudogenes are functionless junk, (2) terminological dogma reinforces a mindset that pseudogenic regions are intrinsically non-functional, and (3) technological limitations prevent us from discovering their function. The paper acknowledges that problem (3) stems from problem (2), but it fails to explicitly recognize that both problems (2) and (3) ultimately stem from problem (1). In fact it doesnt even identify problem (1) as a problem. Yet the whole situation traces back to bad evolutionary predictions. Lets look at these causes briefly, in reverse order:

The proximal cause that prevents us from understanding pseudogene functions are technological limitations. Because of the junk DNA paradigm, a lot of our biochemical techniques and technologies are set up only to identify standard protein-coding genes. They ignore and dismiss DNA that doesnt fit that mold. Only by updating our technology to detect functional DNA elements that dont necessarily fit the standard definition of a gene can be we begin to understand what pseudogenes really do. The paper explains that technical limitations, informed by our biases and assumptions, demotivate the study of pseudogene functions:

In addition to the demotivation into exploring pseudogene function by the apriori assumption that they are functionless, their systematic study has also been hindered by a lack of robust methodologies capable of distinguishing the biological activities of pseudogenes from the functions of the genes from which they are derived.

They compare the situation to that of long non-coding RNAs (lncRNAs), which were similarly dismissed initially as emanating from junk DNA or as transcriptional noise, largely by virtue of their definition as non-protein-coding. But as technology developed, lncRNAs are now widely recognized as functional and we regularly screen for their functions:

Following a combination of technology developments, genome-wide studies and detailed biochemical studies, lncRNAs are now routinely included in genome-wide analyses, and their functional potential as cellular regulators is widely recognized.

However, at present, the authors note, due in part to the experimental challenge of investigating their function and expression, pseudogenes are typically excluded from genome-wide functional screens and expression analyses. In other words, one of the main reasons we arent finding function for pseudogenes is because we arent looking for it. This needs to change, and they argue that it can.

For example, according to the paper, processed pseudogenes were presumed to have been rendered transcriptionally silent by the loss of cis-regulatory elements. But we now know that thousands of retrotransposed gene copies are transcribed and are often spliced into known protein-coding transcripts and up to 10,000 mouse pseudogenes have evidence of transcription. By trying to study these transcripts we can understand what they may be doing.

One complication is that pseudogene transcription shows cell-type specificity and dynamic expression meaning they may only be transcribed in particular places at particular times. This is all the more reason not to assume that lack of evidence for the function of a pseudogene is evidence that the pseudogene has no function! It very likely may be functional in a cell-type or a situation that we just havent properly investigated yet. As they put it, The use of assays ill-suited to analysis of pseudogenes has arguably stymied elucidation of their biological roles. But they are hopeful: CRISPR-based approaches, carefully applied, have the potential to revolutionize our ability to dissect the functions of pseudogenes. They conclude that its time to stop excluding pseudogenes from biochemical analyses and start using techniques that can identify their functions:

The use of a liberal definition of pseudogenes is attractive as it simplifies genomic analyses. This approach, often unknowingly to the researcher, leads to the consolidation of the pseudogene classification that is, their exclusion by convenience in functional studies. Many regions now considered to be dead genes potentially encode cis-regulatory elements, non-coding RNAs and proteins with impacts in human biology and health. Accordingly, determining the functions of putative pseudogenes warrants active pursuit by their inclusion in functional screens and analyses of genomic, transcriptomic and proteomic data. With innovations in long-read sequencing and CRISPR-based methodologies now readily accessible, the technological limitations that formerly motivated the exclusion from functional investigation are largely resolved.

Until we develop and apply these technologies to put pseudogenes to the proper test, the assumption that they are functionless junk is completely unwarranted. And its not hard to predict what the outcome will be. As Ayala and Balakirev noted, pseudogenes that have been suitably investigated often exhibit functional roles. Or as this new paper observes, Where pseudogenes have been studied directly they are often found to have quantifiable biological roles.

Technology only reflects what people want to do, and there are reasons why biologists have created hardly any technology to investigate pseudogenes: biologists presume (wrongly) that pseudogenes are nonfunctional junk. The paper argues that the terminology associated with the junk DNA paradigm discourages investigation into their function. Thus, we have terms like pseudogene which by their very nature imply that the DNA isnt a gene but something like a wannabe gene that doesnt do anything. As the authors note, the definition of a pseudogene as defective means the non-functionality of pseudogenes remains the dominant and default perception. Citing Thomas Kuhn and his concept of a dominant paradigm that is intolerant of criticisms, they lash the junk-pseudogene paradigm in strong terms:

[T]he term pseudogene itself asserts a paradigm of non-functionality through its taxonomic construction. Pseudogenes are defined as defective and not genes. This point is highlighted because impartial language in science is known to inherently restrict the neutral investigation between conflicting paradigms. In the case of pseudogenes, the term itself is constructed to support the dominant paradigm and therefore limit, consciously or unconsciously, scientific objectivity in their investigation.

Its hard to imagine a greater indictment of the idea that pseudogenes are generally functionless. They continue to explain how use of the term pseudogene hinders scientific research:

Although the pseudogene concept arose to describe an individual molecular phenomenon, the term was rapidly adopted to annotate tens of thousands of genomic regions that met only loosely defined criteria and was effectively axiomatized without being subject to any rigorous scientific debate. This lack of consensus-seeking process has left genome biology with a legacy concept that obscures objective investigation of genome function.

They recommend using different language where [t]he automated classification of gene-like sequences as pseudogenes should be avoided. Instead, we propose that descriptive terms that do not make functional inferences should be used in reference to genomic elements that arose from gene duplication and retrotransposition and terminology should not impose any unsubstantiated assumption on end users.

So what is now stopping us from elucidating the functions of pseudogenes? The only obstacle is a mental block not a technical or evidential one:

The dominant limitation in advancing the investigation of pseudogenes now lies in the trappings of the prevailing mindset that pseudogenic regions are intrinsically non-functional.

The paper predicts that as soon as we lose this mindset, there will remain no technical limitations blocking us from progress in understanding the functions of pseudogenes: With renewed scientific objectivity, we anticipate that a wealth of discoveries to understand genome function, its role in disease and the development of new treatments is within reach.

Thats good news, but we must ask a question the paper fails to ask: Why did this terminology develop in the first place?

Evolutionary thinking is the cause that ultimately created, nurtured, and sustained the junk DNA paradigm. Yet the paper adopts a wholly evolutionary approach, and for this reason never identifies evolutionary thinking as the root problem. The closest the authors get is when they recount how the very first paper to identify a pseudogene (published in 1977) dismissed its potential function as a relic of evolution:

In the absence of evidence that the 5S pseudogenes were transcribed, Jacq etal. concluded that the most probable explanation for the existence of the pseudogenes is that they are a relic ofevolution and are functionless1. Since the coining of the term pseudogene, its definition has broadened and is now widely accepted to define any genomic sequence that is similar to another gene and is defective.

This 1977 paper by Jacq et al. was published in the journal Cell and found a pseudogene in an African frog. That paper concluded:

We are thus forced to the conclusion that the most probable explanation for the existence of the pseudogene is that it is a relic of evolution. During the evolution of the 55 DNA of Xenopus laevis, a gene duplication occurred producing the pseudogene. Presumably the pseudogene initially functioned as a 55 gene, but then, by mutation, diverged sufficiently from the gene in its sequence so that it was no longer transcribed into an RNA product.

And there you have it: The pseudogene is seen as a mere a relic produced by mutation until it diverged so much that it was no longer transcribed into an RNA product. This is the classic view of a pseudogene.

Ironically, the 1977 paper went on to speculate that perhaps there is evidence for function for the pseudogene, but the authors privilege the relic view as the right answer until a function can be proven:

This evolutionary explanation for the presence of the pseudogene, however, is incomplete by itself in that it ignores the conservation in sequence of the pseudogene, and indeed of the entire G + C-rich spacer of 55 DNA. In an attempt to explain this, it has been suggested that the pseudogene may be a transcribed spacer corresponding to a primary transcript of 55 RNA, which is a transient precursor and has not so far been detected. If this is so, then most of the G + C-rich region of 55 DNA would be the structural gene for 5S RNA. This function, if true, would provide the necessary selective pressure to conserve the sequence of the linker and pseudogene region so that the correct processing of the postulated 300-long precursor was maintained. In the absence of any experimental evidence for such a long precursor, however, this suggestion must be regarded as speculative; it is more probable that the pseudogene is a relic of evolution.

The recent Nature Reviews Genetics paper hopes to remedy this problem by reviewing much of the overwhelming evidence for pseudogene function and emphasizing how the the non-functionality of pseudogenes remains the dominant and default perception. This will limit, consciously or unconsciously, scientific objectivity in their investigation. The authors are to be commended. However, experience teaches that unless you address the root cause of a problem, it rarely goes away. The tendency to view pseudogenes as a relic of evolution probably wont change as long as you presume that the entire genome is the product of blind evolution. The paper fully endorses the latter view, providing all kinds of narrative gloss that describes pseudogenes (whether functional or not) as retrocopies that arose from gene duplication and transposition. They emphasize:

In the fundamental reductionist approach often assumed in genetics and molecular biology, the perspective is often lost that life as we observe it today is not only the product of billions of years of evolutionary processes but also still subject to these same processes.

They are welcome to take the reductionist approach often assumed in genetics and molecular biology. But until those fundamental evolutionary views of the genome are on the table for questioning, they wont make much progress in shaking the science-stopping assumptions of the junk-DNA paradigm.

Photo: Xenopus laevis, by Brian Gratwicke [CC BY 2.0], via Wikimedia Commons.

More:
Nature Reviews Genetics Pseudogene Function Is Prematurely Dismissed - Discovery Institute

‘I would have had another kid’: How an imperfect gene test led to major surgeryand big regrets – The Daily Briefing

When Katy Mathes and six of her family members learned they had a mutation on a BRCA gene that significantly raised their risk of breast cancer they underwent major surgery. But years later, the genetic testing company lowered the family's odds of getting the disease, Amy Dockser Marcus reports for the Wall Street Journal.

In August 2015, Mathes decided to get a BRCA test. Mathes' mother had been diagnosed with breast cancer at 49, and four of her aunts had tested positive for the BRCA gene, and "moved quickly to get surgery," Dockser Marcus reports.

Mathes and her sister, Tricia Leigh, also had positive tests. The test results showed that Mathes had up to an 84% risk of developing breast cancer by age 70 and up to a 27% risk of developing ovarian cancer by age 70. Among the general population, the odds of developing breast or ovarian cancer are 7.3% and 0.7%, respectively, Dockser Marcus reports.

But the two women grappled over the decision of whether to get surgery: Mathes wanted another child and her sister was breastfeeding her second child.

After consulting with additional doctors, Mathes eventually decided to have her ovaries and fallopian tubes removed, the same procedure her aunts, sister, and mother underwent. In addition, Mathes and her sister had double mastectomies.

"I treated my test results like the Bible," Mathes said. "There was no questioning the report."

But years after the initial test, Myriad Genetics, the molecular diagnostics company that did Mathes' test as well as her relatives', changed its classification of the BRCA variant Mathes has from "pathogenic" to "unknown significance," a move that Myriad said is very unusual.

By this point, Mathes and six of her family members had undergone surgery based on their test results. When the sisters learned the news, Mathes said, "My brain just shut off."

Susan Manley, SVP of medical services at Myriad and a board-certified genetic counselor, said, "We know these are very difficult situations. We make these reclassifications very carefully. The science is evolving." She added that changing a classification from harmful to uncertain "is a rare event, but I understand that rare is of no consolation to the patient when it happens to them."

BRCA tests are among the most common genetic tests in existence, Dockser Marcus writes, and genetic testing guidelines have expanded who should receive BRCA tests. Major genetic testing companies such as 23andMe, Ancestry, and MyHeritage now offer the tests for BRCA1 and BRCA2 genes.

However, not every lab agrees on the specific classification of a BRCA gene variant, Dockser Marcus reports. That's in part because there are "tens of thousands of BRCA variants" and not all of them necessarily carry the same level of risk for a patient, Dockser Marcus reports.

Fergus Couch, a professor at the Mayo Clinic, said some variants "have intermediate or moderate levels of risk, not full-blown risk." For a number of those variants, labs "are making a judgment call but that is not always clear to the public," Couch said.

Stephen Chanock, a geneticist at the National Cancer Institute, said, "[G]enetics is murky." He added, "It's not so simple as 'Doctor, do I have to worry or don't I have to worry?'"

According to Melissa Cline, a researcher at the University of California Santa Cruz Genomics Institute, and project manager of the BRCA Exchange, the analysis on the BRCA variant in the Mathes' family put a lot of weight on a 2011 paper that found the variant likely alters the BRCA2 protein, which can help suppress tumors.

Seth Marcus, a genetic counselor at Advocate Health Care who counseled Mathes' mother and one of her aunts, said he checked a public database to see how other labs classify the variant once he heard of Myriad's change. He said six labs still classify the variant as "likely pathogenic."

"In the end, you give the patient the data and the knowledge you know," he said.

Dockser Marcus reports that Myriad currently has 38 people in its database with the BRCA variant Mathes and her relatives have, 12 of whom come from Mathes' family. Mathes said that if she had known about the sample size, she and her husband may have asked more questions about whether surgery was appropriate.

Now, based on Mathes' family history and Myriad's classification change, Mathes' genetic counselor estimated her lifetime risk of developing breast cancer is 21%, Dockser Marcus writes.

"That is not high enough to make me remove organs," Mathes said. "I would have had another kid. I would have waited to do surgery" (Dockser Marcus, Wall Street Journal, 12/20/19).

See the original post here:
'I would have had another kid': How an imperfect gene test led to major surgeryand big regrets - The Daily Briefing